Want to see BICX full AI Analyst Report?
BICX Stock Chart & Stats
$0.30
$0.05(20.00%)
At close: 4:00 PM EDT
$0.30
$0.05(20.00%)
Day’s Range― - ―
52-Week Range$0.15 - $1.28
Previous CloseN/A
Volume543.00
Average Volume (3M)824.00
Market Cap
$4.42M
Enterprise Value$13.26
Total Cash (Recent Filing)$21.24K
Total Debt (Recent Filing)$2.25M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding29,055,548
10 Day Avg. Volume1,315
30 Day Avg. Volume824
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.48
Price to Sales (P/S)6.75
P/FCF Ratio-2.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$971.85K
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe approximately 71% gross margin indicates that the underlying services or products can generate attractive contribution economics. If revenue scales and operating costs are controlled, this provides a foundation for improving profitability over time.
Historical Revenue ExpansionThe sharp revenue step-up in 2025 suggests the company has demonstrated some ability to expand its commercial base. Sustaining that higher level could improve operating leverage, although recent TTM revenue performance remains weaker.
Reported EPS GrowthReported EPS growth provides a limited positive signal that per-share performance has improved in the measured period. However, it must be viewed alongside deeply negative earnings, so durable value depends on achieving sustained operating profitability.
Bears Say
Deep Operating LossesLosses are extremely large relative to the revenue base, showing that current scale does not support the cost structure. Persistent negative EBIT, EBITDA and net income reduce financial flexibility and make a durable return to profitability uncertain.
Negative Equity And Solvency RiskThe substantial equity deficit leaves little balance-sheet protection for stakeholders and raises recapitalization or solvency risk. Debt alongside negative equity can constrain investment capacity and increase dependence on external financing.
Persistent Cash BurnThe company is consuming cash rather than funding operations internally, indicating that losses have a direct effect on liquidity. Unless operating performance improves materially, continued cash burn may require external capital and dilute financial resilience.
BioCorRx News
BICX FAQ
What was BioCorRx Inc’s price range in the past 12 months?
BioCorRx Inc lowest stock price was $0.15 and its highest was $1.28 in the past 12 months.
What is BioCorRx Inc’s market cap?
BioCorRx Inc’s market cap is $4.42M.
When is BioCorRx Inc’s upcoming earnings report date?
BioCorRx Inc’s upcoming earnings report date is Aug 17, 2026 which is today.
How were BioCorRx Inc’s earnings last quarter?
BioCorRx Inc released its earnings results on Aug 14, 2025. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.
Is BioCorRx Inc overvalued?
According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued.
Does BioCorRx Inc pay dividends?
BioCorRx Inc does not currently pay dividends.
What is BioCorRx Inc’s EPS estimate?
BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioCorRx Inc have?
BioCorRx Inc has 29,055,548 shares outstanding.
What happened to BioCorRx Inc’s price movement after its last earnings report?
BioCorRx Inc reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioCorRx Inc?
Currently, no hedge funds are holding shares in BICX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCorRx Inc
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Technical Analysis
XWELL
―
NewGenIvf Group
―
Mobile-health Network Solutions Class A
―
Basel Medical Group Ltd
―
20/20 Biolabs, Inc.
―